Altimmune Inc (NASDAQ: ALT) kicked off on Friday, up 0.74% from the previous trading day, before settling in for the closing price of $4.05. Over the past 52 weeks, ALT has traded in a range of $2.90-$11.16.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 3.48%. While this was happening, its average annual earnings per share was recorded 7.66%. With a float of $80.26 million, this company’s outstanding shares have now reached $81.11 million.
Let’s determine the extent of company efficiency that accounts for 59 employees. In terms of profitability, gross margin is -205.0%, operating margin of -490965.0%, and the pretax margin is -454605.0%.
Altimmune Inc (ALT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Altimmune Inc is 1.04%, while institutional ownership is 47.42%. The most recent insider transaction that took place on Mar 17 ’25, was worth 5,784. In this transaction Director of this company bought 1,000 shares at a rate of $5.78, taking the stock ownership to the 1,000 shares. Before that another transaction happened on Mar 13 ’25, when Company’s Chief Financial Officer bought 10,000 for $5.20, making the entire transaction worth $51,996. This insider now owns 10,000 shares in total.
Altimmune Inc (ALT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.73% during the next five years compared to 3.48% growth over the previous five years of trading.
Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators
Take a look at Altimmune Inc’s (ALT) current performance indicators. Last quarter, stock had a quick ratio of 15.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16546.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.25, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.31 in one year’s time.
Technical Analysis of Altimmune Inc (ALT)
Looking closely at Altimmune Inc (NASDAQ: ALT), its last 5-days average volume was 3.35 million, which is a drop from its year-to-date volume of 3.9 million. As of the previous 9 days, the stock’s Stochastic %D was 18.95%.
During the past 100 days, Altimmune Inc’s (ALT) raw stochastic average was set at 24.43%, which indicates a significant decrease from 45.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.35 in the past 14 days, which was lower than the 0.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.48, while its 200-day Moving Average is $6.34. However, in the short run, Altimmune Inc’s stock first resistance to watch stands at $4.20. Second resistance stands at $4.33. The third major resistance level sits at $4.40. If the price goes on to break the first support level at $4.00, it is likely to go to the next support level at $3.93. Now, if the price goes above the second support level, the third support stands at $3.80.
Altimmune Inc (NASDAQ: ALT) Key Stats
The company with the Market Capitalisation of 330.92 million has total of 81,107K Shares Outstanding. Its annual sales at the moment are 20 K in contrast with the sum of -95,060 K annual income. Company’s last quarter sales were recorded 10 K and last quarter income was -19,580 K.
